These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 8895687)

  • 21. [Alfa-2a interferon induces molecular remission in post-BMT relapse of chronic myelogenous leukaemia. Report of a case with loss of bcr-abl RNA].
    Casado LF; Steegmann JL; Picó M; Requena MJ; Gómez C; Fernández-Rañada JM
    Sangre (Barc); 1995 Oct; 40(5):417-20. PubMed ID: 8553177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
    Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Br J Haematol; 1995 Sep; 91(1):126-31. PubMed ID: 7577619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
    Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A long-term suppression by alpha-interferon of Philadelphia chromosome in children with chronic myelogenous leukemia.
    Kikawa Y; Fuji Y; Takano T; Shigematsu Y; Sudo M; Okamoto M; Mizutani S
    Acta Paediatr Jpn; 1993 Aug; 35(4):361-4. PubMed ID: 8379332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia.
    Kiss TL; Xu WM; Jamal N; Messner HA
    Leuk Lymphoma; 1999 Aug; 34(5-6):493-500. PubMed ID: 10492072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
    Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
    Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia.
    Buño I; Wyatt WA; Zinsmeister AR; Dietz-Band J; Silver RT; Dewald GW
    Blood; 1998 Oct; 92(7):2315-21. PubMed ID: 9746769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia.
    Hessner MJ; Roth MS; Drobyski WR; Baxter-Lowe LA
    Genet Anal Tech Appl; 1994; 11(4):90-4. PubMed ID: 7857690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
    Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
    Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
    J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
    Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
    Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy.
    Shtalrid M; Talpaz M; Blick M; Romero P; Kantarjian H; Taylor K; Trujillo J; Schachner J; Gutterman JU; Kurzrock R
    J Clin Oncol; 1988 Oct; 6(10):1569-75. PubMed ID: 3171624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse transcriptase-polymerase chain reaction for bcr/abl fusion in chronic myelogenous leukemia.
    Wells SJ; Phillips CN; Winton EF; Farhi DC
    Am J Clin Pathol; 1996 Jun; 105(6):756-60. PubMed ID: 8659451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
    Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
    Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
    Hochhaus A; Lin F; Reiter A; Skladny H; Mason PJ; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Blood; 1996 Feb; 87(4):1549-55. PubMed ID: 8608246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
    Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
    Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
    González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
    Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
    Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
    J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.